Cannabis‐Based Medicinal Products for Endometriosis: A 2‐Year Prospective Analysis From the UK Medical Cannabis Registry
Australian and New Zealand Journal of Obstetrics and Gynaecology · 2026
DOI: 10.1111/ajo.70173 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Australian and New Zealand Journal of Obstetrics and Gynaecology, 2026. Verfasst von Tania Ahmed und 14 weiteren Autor:innen. Beteiligte Einrichtung: Medical Cannabis Research Group, Imperial College London, London, UK. Hauptthemen laut MEDLINE: Endometriosis, Medical Marijuana, Pelvic Pain. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Endometriosis affects up to 10% of biological females of reproductive age. Current treatment options are limited and often unsuitable for prolonged use. Cannabis‐based medicinal products (CBMPs) have emerged as an alternative for pain management.
Aims
To analyse changes in patient‐reported outcome measures (PrOMs), prescribed opioid burden, and the prevalence of adverse events (AEs) in patients prescribed CBMPs for endometriosis‐associated pain. Materials and Methods This was an observational analysis of prospectively collected data from the UK Medical Cannabis Registry. Biological females (≥ 18 years) with a primary diagnosis of endometriosis, enrolled ≥ 2 years prior to data extraction on 06/01/2025, were included. PrOMs and prescribed oral morphine equivalents (OME) were assessed between baseline and 1, 3, 6, 12, 18, and 24 months. Changes from baseline were assessed by repeated‐measures ANOVA and Bonferroni‐adjusted post hoc pairwise t‐tests. p < 0.050 was considered statistically significant.
Results
One hundred and one patients were included. Improvements from baseline were observed in BPI Severity, BPI Interference, SF‐MPQ‐2 Total, Pain VAS, EQ‐5D‐5L Index, GAD‐7, and SQS at all follow‐ups ( p < 0.001). Mean prescribed OME decreased from 19.9 ± 17.2 mg/day at baseline to 14.8 ± 15.9 mg/day at 24 months. Eighteen participants (17.8%) reported 165 AEs, of which 84 (50.9%) were mild. The most frequent were fatigue ( n = 16; 15.8%), lethargy ( n = 15; 14.9%), and headache ( n = 13; 12.9%).
Conclusion
CBMP treatment was associated with sustained improvements in pain, health‐related quality of life, sleep, and anxiety at 24 months, with a favourable AE profile. Randomised controlled trials are required to establish efficacy and safety.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Cannabis Research Group, Imperial College London, London, UK.
- Curaleaf Clinic, London, UK.
- St. George's Hospital NHS Trust, London, UK.
- North Bristol NHS Trust, Bristol, UK.
- Cardiff and Vale University Health Board, Cardiff, UK.
- Department of Psychological Medicine, Kings College London, London, UK.
ORCID-Profile: Tania Ahmed, Simon Erridge, James J Rucker, Michael Platt
Zitieren
APA
Ahmed, T., Erridge, S., Clarke, E., McLachlan, K., Coomber, R., Barnes, S., Medniuk, A. D., Guru, R., Holden, W., Sajad, M., Searle, R., Usmani, A., Rucker, J. J., Platt, M., & Sodergren, M. H. (2026). Cannabis‐Based Medicinal Products for Endometriosis: A 2‐Year Prospective Analysis From the UK Medical Cannabis Registry. Australian and New Zealand Journal of Obstetrics and Gynaecology. https://doi.org/10.1111/ajo.70173
Vancouver
Ahmed T, Erridge S, Clarke E, McLachlan K, Coomber R, Barnes S, et al. Cannabis‐Based Medicinal Products for Endometriosis: A 2‐Year Prospective Analysis From the UK Medical Cannabis Registry. Australian and New Zealand Journal of Obstetrics and Gynaecology. 2026. doi:10.1111/ajo.70173
BibTeX
@article{Ahmed2026,
author = {Ahmed, Tania and Erridge, Simon and Clarke, Evonne and McLachlan, Katy and Coomber, Ross and Barnes, Shelley and Medniuk, Alia Darweish and Guru, Rahul and Holden, Wendy and Sajad, Mohammed and Searle, Robert and Usmani, Azfer and Rucker, James J and Platt, Michael and Sodergren, Mikael H},
title = {Cannabis‐Based Medicinal Products for Endometriosis: A 2‐Year Prospective Analysis From the UK Medical Cannabis Registry},
journal = {Australian and New Zealand Journal of Obstetrics and Gynaecology},
year = {2026},
doi = {10.1111/ajo.70173}
}
EUVIMED